AbbVie
Key Metrics
How this company measures up on the fundamentals that matter
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Valuation
Trading at $202 against a fair value of $324, a 38% discount. Fails ethical screen (Debt ratio). Ranks better than 70% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Market Data
Trading characteristics and market positioning
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Analyst Coverage
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | Purdue David Ryan | SVP, Controller | Sale | 5,230 | $1,221,519 |
| 2026-03-02 | Siatis Perry C | EVP, GC, SECRETARY | Sale | 18,668 | $4,375,549 |
| 2026-02-25 | Siatis Perry C | EVP, GC, SECRETARY | Sale | 22,381 | $5,147,630 |
| 2025-08-12 | Saleki-Gerhardt Azita | EVP, CHIEF OPERATIONS OFFICER | Sale | 42,370 | $8,407,055 |
| 2025-08-05 | Donoghoe Nicholas | EVP, CHIEF BUS, STRAT OFFICER | Sale | 13,295 | $2,639,253 |
Political Trading Activity
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 5 May2026 | Josh Gottheimer | Democrat | sell | 1K–15K |
| 2026-04-13 | Ro Khanna | Democrat | Sale | 15K–50K |
| 15 May2026 | Ro Khanna | Democrat | buy | 15K–50K |
| 1 May2026 | Ro Khanna | Democrat | buy | 15K–50K |
What If You'd Bought ABBV?
| Period | Price Then | Price Return | Divs/Share | $1,000 Became | Total Return |
|---|---|---|---|---|---|
| 1 Month | $202.78 | +11.4% | — | $1,114 | +11.4% |
| 2 Months | $206.23 | +9.6% | $1.73 | $1,104 | +10.4% |
| 3 Months | $223.52 | +1.1% | $1.73 | $1,018 | +1.8% |
| 6 Months | $220.36 | +2.5% | $3.46 | $1,041 | +4.1% |
| 1 Year | $183.52 | +23.1% | $6.74 | $1,268 | +26.8% |
| 2 Years | $159.30 | +41.8% | $13.12 | $1,501 | +50.1% |
| 3 Years | $124.09 | +82.1% | $19.18 | $1,975 | +97.5% |
| 5 Years | $95.69 | +136.1% | $30.38 | $2,678 | +167.8% |
Historical returns. Past performance does not guarantee future results. Prices from market close data.
Framework Review History
Timestamped framework reads — tracking how the analysis evolves over time
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Latest Analysis — ABBV
Timestamped intelligence from our daily research pipeline
AbbVie (ABBV) Case Study | Titan Protect * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', system-ui, -apple-system, sans-serif; line-height: 1.7;...
4502.T Case Study: Takeda Pharmaceutical | Titan Macro Desk * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; line-height:...
Shariah Compliance Verdict FAIL AbbVie fails the debt purity screen decisively. High leverage from acquisition-driven debt makes it non-compliant under standard Shariah screening criteria. AbbVie Inc. (NYSE: ABBV) is a...
12 June 2026 • Alpha Insights Sector Research Top 50 Healthcare Stocks Ranked: Pharma, Biotech, and MedTech Scored for Quality and Ethics Healthcare has become the quiet defensive rotation of...
🛡️ OVERWATCH“Jobs Data or Just Drama? SPX Holds, Tech Staggers, Vol Explodes”📆 Friday, August 1, 2025 | ⏰ 08:30 BST / 03:30 EST📦 Status: Pre-NFP Positioning, Defensive Tilt, Volatility Expansion...
🛡️ Earnings Echo “Split Signals, Spiking Stakes — Energy Clouds the AI Narrative” 📆 Friday, August 1, 2025 | ⏰ 08:30 BST / 03:30 EST📦 Status: Tech Diverges, Energy Wavers,...
🛡️ OVERWATCH Microsoft & Meta Face the Market — Will the AI Boom Break or Accelerate? 📆 Wednesday, 30 July 2025 | ⏰ 19:00 BST / 14:00 EST📦 Status: Compression...
🛡️ Earnings EchoMicrosoft & Meta: The Moment of Truth — Will AI Pay or Break the Market?📆 Wednesday, July 30, 2025 | ⏰ 18:30 BST / 13:30 EST📦 Status: Calm...
Data sourced from public filings and market feeds. Not financial advice. Updated: 2025-12-31